ASX:PAR Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Paradigm Biopharmaceuticals Stock (ASX:PAR) 30 days 90 days 365 days Advanced Chart Get PAR alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.81 million shsAverage VolumeN/AMarket Capitalization$196.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewParadigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.Read More… Receive PAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PAR Stock News HeadlinesThis stock could have something close to a cure for osteoarthritis. Don’t let it hide under your noseMay 20, 2025 | msn.comIHS Holding Limited: IHS Towers Agrees to Sell Rwanda Operations to Paradigm Tower VenturesMay 20, 2025 | finanznachrichten.deElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 24, 2025 | Brownstone Research (Ad)IHS Towers Agrees to Sell Rwanda Operations to Paradigm Tower VenturesMay 20, 2025 | finance.yahoo.comBiopharmaceuticals Market Forecast Report 2025-2034: Oncology Segment Captured 30.9% Share in 2024 Amid Surge in Targeted Cancer TherapiesMay 16, 2025 | finance.yahoo.comCressey & Company Announces Partnership with Leading Hospice Provider, Paradigm HealthMay 12, 2025 | finance.yahoo.comParadigm Signs ‘Virgin River’ & ‘The Good Doctor’ Director Felipe RodriguezMay 9, 2025 | msn.comIs Paradigm Biopharmaceuticals (ASX:PAR) In A Good Position To Invest In Growth?March 30, 2025 | finance.yahoo.comSee More Headlines PAR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Paradigm Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), Mesoblast (MESO), CytoDyn (CYDY), Bubs Australia (BUB), Blue Energy (BLU) and BHP Group (BHP). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryComputer Hardware Current SymbolASX:PAR CIKN/A Webwww.paradigmbiopharma.com Phone61 3 9629 5566FaxN/AEmployees1,480Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,650,000.00 Net Margins-89,138.58% Pretax MarginN/A Return on Equity-203.64% Return on Assets-86.16% Debt Debt-to-Equity Ratio1.01 Current Ratio7.22 Quick Ratio5.93 Sales & Book Value Annual Sales$79,224.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow6.44 Book ValueA$0.08 per share Price / BookN/AMiscellaneous Outstanding Shares350,360,000Free FloatN/AMarket Cap$196.66 million OptionableNot Optionable Beta0.94 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (ASX:PAR) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paradigm Biopharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Paradigm Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PAR Stock Free PAR Stock Alerts